Trial Condition(s):

Clinical Pharmacology

BAY59-7939, comparison of PK of Rivaroxaban and Apixaban

Bayer Identifier:

18359

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2015-002612-32

EU CT Number:

Not Available

Study Completed

Trial Purpose

To assess the plasma pharmacokinetics (PK) of
rivaroxaban and apixaban after multiple dosing and after
discontinuation of both.

Inclusion Criteria

:
  - Healthy male white subjects age 18 to 55 years (inclusive) with a
body mass index above or equal 18.0 kg/m² and below or equal
29.9 kg/m²

Exclusion Criteria

No Exclusion Criteria Available

Trial Summary

Enrollment Goal

N/A

Trial Dates

September2015

February2016

Phase

Could I receive a placebo?

Products

Xarelto (Rivaroxaban, BAY59-7939)

Accepts Healthy Volunteers

Yes

Where to Participate

Locations

Locations
Locations Investigative Site Mönchengladbach, Germany, 41061	Contact Us: E-mail: [email protected] Phone: Not Available

Investigative Site

Mönchengladbach, Germany, 41061

Contact Us:

E-mail: [email protected]

Phone: Not Available

Clinical Pharmacology

Bayer Identifier:

ClinicalTrials.gov Identifier:

EudraCT Number:

EU CT Number:

Trial Purpose

Key Participation Requirements

sex

age

18 Years

55 Years

Inclusion Criteria

Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Trial Summary

Enrollment Goal

Trial Dates

Phase

Could I receive a placebo?

Products

Accepts Healthy Volunteers

Where to Participate

For details, please refer to trial results

Additional Information